Despite the delays in the launch of Advair’s generic, Hikma has slightly upgraded its FY20 guidance – on the back of strong underlying demand for new launches, especially, a generic version of Vascepa. Management seems confident of Advair’s generic launch early next year and we reiterate our $150-200m peak sales potential for the drug.
10 Nov 2020
FY20 guidance upgraded led by new drug launches
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY20 guidance upgraded led by new drug launches
Hikma Pharmaceuticals Plc (HIK:LON) | 1,926 732 2.0% | Mkt Cap: 4,274m
- Published:
10 Nov 2020 -
Author:
Rishabh Kochar -
Pages:
2
Despite the delays in the launch of Advair’s generic, Hikma has slightly upgraded its FY20 guidance – on the back of strong underlying demand for new launches, especially, a generic version of Vascepa. Management seems confident of Advair’s generic launch early next year and we reiterate our $150-200m peak sales potential for the drug.